Cargando…

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events

Biologics targeting PD-1, PD-L1, and CTLA-4 immune checkpoint proteins have been used in a variety of tumor types including small and non-small cell lung cancers, melanoma, and renal cell carcinoma. Their anti-tumor activity is achieved through amplifying components of the patient’s own immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makunts, Tigran, Burkhart, Keith, Abagyan, Ruben, Lee, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830697/ https://www.ncbi.nlm.nih.gov/pubmed/35143542 http://dx.doi.org/10.1371/journal.pone.0263402

Ejemplares similares

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
por: Cohen, Isaac V., et al.
Publicado: (2020)

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites
por: Makunts, Tigran, et al.
Publicado: (2020)

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
por: Makunts, Tigran, et al.
Publicado: (2023)

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids
por: Makunts, Tigran, et al.
Publicado: (2019)

Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
por: Makunts, Tigran, et al.
Publicado: (2019)

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory
por: Makunts, Tigran, et al.
Publicado: (2019)

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
por: Wollmer, M. Axel, et al.
Publicado: (2021)

Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain
por: Makunts, Tigran, et al.
Publicado: (2018)

How can proton pump inhibitors damage central and peripheral nervous systems?
por: Makunts, Tigran, et al.
Publicado: (2020)

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023)

Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
por: Cohen, Isaac V., et al.
Publicado: (2021)

Common osteoporosis drug associated with increased rates of depression and anxiety
por: Keshishi, Dro, et al.
Publicado: (2021)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022)

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data
por: Makunts, Tigran, et al.
Publicado: (2021)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Predicting potential adverse events using safety data from marketed drugs
por: Daluwatte, Chathuri, et al.
Publicado: (2020)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
por: Shah, N., et al.
Publicado: (2019)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
por: Zhou, Jiang-Min, et al.
Publicado: (2023)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2020)

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus
por: Jono, Misato, et al.
Publicado: (2019)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event
por: Doodnauth, Andrew V, et al.
Publicado: (2021)

Adverse events of sugammadex that occurred in a Korean population
por: Han, Woong, et al.
Publicado: (2022)

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus
por: Takemura, Masao, et al.
Publicado: (2021)

A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

Pancreatitis as immune‐related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer
por: Kokura, Kazuki, et al.
Publicado: (2023)

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study
por: Egami, Saeka, et al.
Publicado: (2021)

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2021)

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy
por: Tamanoi, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q62db1rcmufg6gtcd9addjlojn